Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 6/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.33 |
| ▸ | CDK7 | P50613 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469475 | 0.84 | HTR1D (0.46) | TTKPRMT1CARM1 | |
| SCHEMBL16120045 | 0.83 | TTK (0.39) | SIGMAR1TTKPRMT1CARM1ROCK2 | |
| SCHEMBL17469471 | 0.82 | TTK (0.48) | TTKPRMT1LRRK2 | |
| SCHEMBL16129386 | 0.82 | MTNR1A (0.43) | SIGMAR1TTKPRMT1CARM1ROCK2 | |
| SCHEMBL16129434 | 0.82 | LRRK2 (0.36) | SIGMAR1TTKPRMT1CDK2PRMT6 | |
| SCHEMBL16129428 | 0.82 | ROCK2 (0.37) | SIGMAR1TTKIGLV6-57PRMT1CARM1 | |
| SCHEMBL17469452 | 0.81 | PRMT1 (0.47) | PRMT1PRMT6LRRK2 | |
| SCHEMBL17469484 | 0.81 | TTK (0.39) | TTKPRMT1LRRK2 | |
| SCHEMBL17469504 | 0.80 | HTR2A (0.44) | PRMT1HTR6LRRK2 | |
| SCHEMBL16129385 | 0.80 | PRMT1 (0.39) | SIGMAR1PRMT1PRMT6ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | SIGMAR1 3623/4885TTK 3253/4885IGLV6-57 4826/4885 |
| US-20180105497-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | SIGMAR1 3623/4885TTK 3253/4885IGLV6-57 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.